enGene Therapeutics Inc. Common Stock

ENGNNASDAQ • USD
2.41 USD
↗ 0.13 (5.70%)AT CLOSE (03:59 PM EST)
2.31
↘ 0.10 (4.15%)
POST MARKET (AS OF 04:14 PM EST)
Post Market
AS OF 04:14 PM EST
2.31
↘ 0.10 (4.15%)
🔴Market: CLOSED

enGene Therapeutics Inc. Common Stock (ENGN) is currently trading at $2.41. There is a divergence between signals — technical indicators rate "Buy" but underlying fundamentals lean "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Nov 13, 2026.

Open?$2.41
High?$2.51
Low?$2.17
Prev. Close?$2.28
Volume?3.7M
Avg. Volume?1.4M
VWAP?$2.33
Rel. Volume?2.68x
Bid / Ask
Bid?$2.25 × 500
Ask?$2.32 × 400
Spread?$0.07
Midpoint?$2.29
Valuation & Ratios
Market Cap?161.5M
Shares Out?67.0M
Float?44.1M
Float %?65.8%
P/E Ratio?N/A
P/B Ratio?0.70
EPS?-$1.95
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
Employees
82
Market Cap
161.5M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2023-11-01
Address
4868 RUE LEVY, SUITE 220
SAINT-LAURENT,
Phone: (514) 332-4888
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
1
Momentum?
50
Short Sent.?
70
Piotroski F-Score?0/9Weak
Altman Z-Score?-1.11Distress
Confidence?47%Low
Full Fundamental Analysis →
Short InterestLow
Short % of Float?3.68%Low
Short Interest?1.6M
Days to Cover?1.9
Free Float44.1M
Avg Daily Volume847.0K
Settlement Date2026-10-30
Financial Health
Current Ratio?10.21Strong
Quick Ratio?10.21Strong
Cash Ratio?1.51Strong
Debt/Equity?0.11Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.70CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.1CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-56.6%WEAK▾
ROA?
S&P
3
-45.2%WEAK▾
Cash Flow & Enterprise
FCF?$-103997000
Enterprise Value?$145.8M
Fundamentals ratios updated end of day